Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

D Cook, D Brown, R Alexander, R March… - Nature reviews Drug …, 2014 - nature.com
Maintaining research and development (R&D) productivity at a sustainable level is one of
the main challenges currently facing the pharmaceutical industry. In this article, we discuss …

Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease

L George, CE Brightling - Therapeutic advances in chronic …, 2016 - journals.sagepub.com
The chronic lung diseases, asthma and chronic obstructive pulmonary disease (COPD), are
common affecting over 500 million people worldwide and causing substantial morbidity and …

Targeting the interleukin pathway in the treatment of asthma

KF Chung - The Lancet, 2015 - thelancet.com
Asthma is a common heterogeneous disease with a complex pathophysiology. Current
therapies based on inhaled corticosteroids and longacting β 2 agonists are effective in …

Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group …

S Gonem, R Berair, A Singapuri, R Hartley… - The Lancet …, 2016 - thelancet.com
Background Eosinophilic airway inflammation is often present in asthma, and reduction of
such inflammation results in improved clinical outcomes. We hypothesised that fevipiprant …

Allergen-induced increases in sputum levels of group 2 innate lymphoid cells in subjects with asthma

R Chen, SG Smith, B Salter, A El-Gammal… - American journal of …, 2017 - atsjournals.org
Rationale: Group 2 innate lymphoid cells (ILC2), a major source of type 2 cytokines, initiate
eosinophilic inflammatory responses in murine models of asthma. Objectives: To investigate …

The prostaglandin D2 receptor CRTH2 regulates accumulation of group 2 innate lymphoid cells in the inflamed lung

ED Tait Wojno, LA Monticelli, SV Tran, T Alenghat… - Mucosal …, 2015 - nature.com
Group 2 innate lymphoid cells (ILC2s) promote type 2 cytokine-dependent immunity,
inflammation, and tissue repair. Although epithelial cell-derived cytokines regulate ILC2 …

Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies

KF Chung - Journal of internal medicine, 2016 - Wiley Online Library
Asthma is a common heterogeneous disease with a complex pathophysiology that carries a
significant mortality rate and high morbidity. Current therapies based on inhaled …

Prostaglandin D2: a dominant mediator of aspirin-exacerbated respiratory disease

KN Cahill, JC Bensko, JA Boyce, TM Laidlaw - Journal of Allergy and …, 2015 - Elsevier
Background Aspirin desensitization followed by high-dose aspirin therapy is routinely
performed for patients with aspirin-exacerbated respiratory disease (AERD). Little is known …

Prostaglandin D2 pathway upregulation: relation to asthma severity, control, and TH2 inflammation

ML Fajt, SL Gelhaus, B Freeman, CE Uvalle… - Journal of allergy and …, 2013 - Elsevier
BACKGROUND: Bronchoalveolar lavage (BAL) fluid prostaglandin D2 (PGD2) levels are
increased in patients with severe, poorly controlled asthma in association with epithelial …

G protein–coupled receptors in asthma therapy: pharmacology and drug action

SG Wendell, H Fan, C Zhang, PA Insel - Pharmacological reviews, 2020 - Elsevier
Asthma is a heterogeneous inflammatory disease of the airways that is associated with
airway hyperresponsiveness and airflow limitation. Although asthma was once simply …